Clinical efficacy and pharmacokinetic study of antituberculosis treatment in patients with end-stage renal disease undergoing hemodialysis
By: Wei Song, Zhao Yang, Yuqian Zhao, Bing Liu, Musong Li, Wei Du, Ning Niu and Jianru Jia
References
- Le Pham NM, Ong TP, Vuong NL, Van Tran B, Nguyen TTH. HLA types and their association with end-stage renal disease in Vietnamese patients: a cross-sectional study. Medicine (Baltimore). 2022; 101: e31856. doi: 10.1097/MD.0000000000031856.
- Rahul N, Yadava R, Raj AS, Jyothi PSA. Pragmatic Ayurveda approach towards end-stage renal disease. J Ayurveda Case Rep. 2025; 8:113–8.
- Ma’bud T. Patients with end-stage renal disease admitted to the intensive care unit: systematic review. J Adv Res Med Health Sci. 2023; 9:70–4.
- Kakar A, Kakar N, Durand AC, Mouelhi Y, Gentile S. Global impact of obesity and diabetes on the increase incidence and prevalence of chronic kidney disease (CKD) and end stage renal disease (ESRD): a systematic review. PREPRINT (Version 1) available at Research Square. 2021. doi.org/10.21203/rs.3.rs-199379/v1
- Doan V, Shoker A, Abdelrasoul A. Quality of life of dialysis patients: exploring the influence of membrane hemocompatibility and dialysis practices on psychosocial and physical symptoms. J Compos Sci. 2024; 8:172. doi: 10.3390/jcs8050172
- Roy A, Sharma M, Kumar Doley P, Pegu G. Intradialytic complications during hemodialysis: a single centre, prospective, observational study. Indian J Appl Res. 2023; 13:1–3.
- Beyene E, Demissie Z, Jote W, Getachew S, Ejigu A, Degu W. Burden of tuberculosis in end stage renal disease patients undergoing maintenance hemodialysis: a multicenter study and experience from Ethiopian dialysis setting. Int J Nephrol Renovasc Dis. 2024; 17:59–69.
- Descamps-Latscha B, Jungers P. Immunological and chronic inflammatory abnormalities in end stage renal disease. Replacement of renal function by dialysis. 2004; 3:1083–102.
- Lu M, Sue YM, Hsu HL, Zhang JF, Liu YJ, Yen YC, et al. Tuberculosis treatment delay and nosocomial exposure remain important risks for patients undergoing regular hemodialysis. J Microbiol Immunol Infect. 2022; 55:926–34.
- Nowak D, Radenbach D, Magnussen H. Chemotherapy of pulmonary tuberculosis. Sputum culture conversion in 8 weeks in 84% of patients. Dtsch Med Wochenschr. 1987; 112:1367–70.
- Shaukat MA, Ali MF, Irtaza A, Khan SY, Khan SM, Babar S. Continuous rifampicin therapy induced acute kidney injury in a tuberculous patient: a case report. Int J Med Stud. 2024; 12:212–8.
- Abdullah, Behera MR, Kaul A, Agarwal V, Prasad P, Prasad N, et al. The unusual adverse effects of antituberculosis therapy in kidney patients. Int J Mycobacteriol. 2024; 13:183–90.
- Rohmah SN, Puspitasari M, Wardhani Y, Ananda NR, Khotijah AA. Diagnostic and therapeutic challenges of tuberculosis in kidney transplant recipients: a case series study. J Nephropharmacol. 2024; 13:e11679.
- Li J, Wang C, Dong HW, Qi J, Rao C, Li Q, et al. Analysis of the onset characteristics and diagnosis of 217 cases of renal tuberculosis. Eur J Med Res. 2025; 30:499.
- Staden DV, Haynes RK, Van der Kooy F, Viljoen JM. Development of a HPLC method for analysis of a combination of clofazimine, isoniazid, pyrazinamide, and rifampicin incorporated into a dermal self-double-emulsifying drug delivery system. Methods Protoc. 2023; 6:104.
- Shakya N, Garg G, Agrawal B, Kumar R. Chemotherapeutic interventions against tuberculosis. Pharmaceuticals. 2012; 5:690–718.
- Jonny J, Saraswati PD, Ramadhani BP, Sitepu EC, Pasiak TF. Update on drug-resistant pulmonary tuberculosis treatment in hemodialysis patients. Indian J Tuberc. 2024; 71 Suppl 1:S110–6.
- Madero M, Levin A, Ahmed SB, Carrero JJ, Foster B, Francis A, et al. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2024 clinical practice guideline. Ann Intern Med. 2025; 178:705–13.
- WHO Guidelines Approved by the Guidelines Review Committee. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization; 2014.
- Expert Group of Blood Purification Center Management Branch of Chinese Hospital Association. Expert consensus on management of chronic kidney disease combined with tuberculosis in Chinese adults. Chin J Blood Purif. 2016; 15:577–86.
- Wang Q, Huang YS, Chen HM, Luo DL. Effect of adjuvant treatment of Mycobacterium phlei on clinical efficacy and immune function in patients with multidrug-resistant tuberculosis. J Clin Pulm Med. 2021; 26:81–5.
- Kim J, Kwak N, Lee HY, Kim TS, Kim CK, Han SK, et al. Effect of drug resistance on negative conversion of sputum culture in patients with pulmonary tuberculosis. Int J Infect Dis. 2016; 42:64–8.
- Zhang TY, Li D, Zhang LT, Wang D, Wang X, Sun Z, et al. Blood drug concentration monitoring results of quadruple anti-tuberculosis drugs in the treatment of bacteriologically positive pulmonary tuberculosis and their relationship with clinical efficacy. Chin J Clin. 2024; 52:47–50.
- Zhai Y. TM. Clinical efficacy and safety of bedaquiline combined with conventional anti-tuberculosis drugs in the treatment of multidrug-resistant tuberculosis. Chin J Clin Ration Drug Use. 2024; 17:83–6.
- Saito N, Yoshii Y, Kaneko Y, Nakashima A, Horikiri T, Saito Z, et al. Impact of renal function-based anti-tuberculosis drug dosage adjustment on efficacy and safety outcomes in pulmonary tuberculosis complicated with chronic kidney disease. BMC Infect Dis. 2019; 19:374.
- Caixia S, Yangjing Q, Zhenyuan Y. Diagnosis and treatment of tuberculosis peritonitis in patients with maintenance hemodialysis. Int J Urol Nephrol. 2018; 38:137–40.
- Herrera-Pérez IG, Rodríguez-Báez AS, Ortiz-Álvarez A, Velarde-Salcedo R, Arriaga-García FJ, Rodríguez-Pinal CJ, et al. Standardization and validation of a novel UPLC-MS/MS method to quantify first line anti-tuberculosis drugs in plasma and dried blood spots. J Chromatogr B. 2023; 1228:123801.
- Sileshi T, Tadesse E, Makonnen E, Aklillu E. The impact of first-line anti-tubercular drugs’ pharmacokinetics on treatment outcome: a systematic review. Clin Pharmacol. 2021; 13:1–12.
- Chigutsa E, Pasipanodya JG, Visser ME, van Helden PD, Smith PJ, Sirgel FA, et al. Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis. Antimicrob Agents Chemother. 2015; 59:38–45.
- Putra ON, Purnamasari T, Hamami NM. Pyrazinamide-induced hyperuricemia in pulmonary tuberculosis patients. Int J Mycobacteriol. 2024; 13:282–7.
- Thumamo Pokam BD, Enoh JE, Eyo AO, Umoh NO, Guemdjom PW. Uric acid levels in patients on antituberculosis drugs in the southwest region of Cameroon. Int J Mycobacteriol. 2018; 7:89–91.
- Muhammad N, Mehboob S, Abbas M. Pyrazinamide induced hyperuricemia in the induction phase of anti-tuberculosis therapy. Pak J Med Health Sci. 2021; 15:1136–8.
- Mondal S, Roy V, Meshram GG, Khanna A, Velpandian T, Garg S. Pharmacokinetics-pharmacodynamics of first-line antitubercular drugs: a comparative study in tuberculosis patients with and without concomitant diabetes mellitus. Eur J Clin Pharmacol. 2024; 80:1945–58.
- Chinese Society for Tuberculosis, Chinese Medical Association. Expert consensus on the treatment of chronic kidney disease with tuberculosis (2022 version). Zhonghua Jie He He Hu Xi Za Zhi. 2022; 45:996–1008. Chinese.
- Gu H, Peng J, Chen A, Yin R, Xiao Q, Chen J. Clinical characteristics and prognostic analysis of maintenance hemodialysis patients with initial treatment tuberculosis. J Kunming Med Univ. 2025; 46:129–35.
Language: English
Page range: 182 - 193
Published on: Jun 30, 2026
Published by: Chulalongkorn University
In partnership with: Paradigm Publishing Services
Related subjects:
© 2026 Wei Song, Zhao Yang, Yuqian Zhao, Bing Liu, Musong Li, Wei Du, Ning Niu, Jianru Jia, published by Chulalongkorn University
This work is licensed under the Creative Commons Attribution 4.0 License.